Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) IN COMBINATION WITH DOCETAXEL (ALBUMIN-BOUND) (HB1801) FOR NEOADJUVANT TREATMENT OF HER

VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) IN COMBINATION WITH DOCETAXEL (ALBUMIN-BOUND) (HB1801) FOR NEOADJUVANT TREATMENT OF HER

March 31, 2026

a260331_00.png

Next: VOLUNTARY ANNOUNCEMENT - INDACATEROL ACETATE AND MOMETASONE FUROATE POWDER FOR INHALATION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC PHARMACEUTICAL GROUP LIMITED All Rights Reserved | 冀ICP备05003393号

Wechat